Amicus Therapeutics (Nasdaq: FOLD), today announced additional 6-month (Stage 1) results from the first ongoing Phase 3 global registration study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE